Analysts at StockNews.com began coverage on shares of Jaguar Health (NASDAQ:JAGX – Get Rating) in a research report issued on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Jaguar Health Stock Up 0.1 %
Shares of NASDAQ JAGX opened at $0.08 on Monday. The company has a debt-to-equity ratio of 5.56, a quick ratio of 0.69 and a current ratio of 0.94. Jaguar Health has a 52 week low of $0.08 and a 52 week high of $0.89. The stock has a market capitalization of $12.30 million, a P/E ratio of -0.09 and a beta of 1.73. The stock’s fifty day moving average is $0.11 and its 200 day moving average is $0.18.
Jaguar Health (NASDAQ:JAGX – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The biotechnology company reported ($0.12) EPS for the quarter. Jaguar Health had a negative return on equity of 823.56% and a negative net margin of 502.84%. The company had revenue of $3.15 million during the quarter. Sell-side analysts forecast that Jaguar Health will post -0.64 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Jaguar Health Company Profile
Jaguar Health, Inc is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea.
- Get a free copy of the StockNews.com research report on Jaguar Health (JAGX)
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.